Bacteriostatic Water · Research brief
Tesamorelin Vial Size — Dosing, Storage & Supply Facts
Short answer
A 2mg tesamorelin vial looks identical to a 1mg vial from the outside. Same cap, same lyophilized powder appearance, same reconstitution requirements. The difference only becomes obvious when you run the math on dosing volume, and by then, researchers have already ordered a three-month supply based on incorrect calculations.
Key takeaways
- Tesamorelin vial size typically ranges from 1mg to 2mg per vial in research-grade formats, with 2mg being the most common specification that balances multi-dose convenience and reconstitution simplicity.
- Reconstitution concentration is determined by dividing total peptide content by bacteriostatic water volume. A 2mg vial mixed with 2mL water yields 1mg/mL, while the same vial mixed with 1mL water yields 2mg/mL.
- Unreconstituted lyophilized tesamorelin remains stable at −20°C for 24–36 months, but once reconstituted with bacteriostatic water, must be refrigerated at 2–8°C and used within 28 days.
- Larger vial sizes reduce the number of reconstitution events required for multi-week protocols, minimizing freeze-thaw cycles and cold-chain shipment frequency.
- Injection volume decreases as reconstitution concentration increases. A 1mg dose from a 2mg/mL solution requires only 0.5mL injection volume versus 1mL from a 1mg/mL solution.
- Temperature excursions above 8°C cause irreversible peptide denaturation that visual inspection cannot detect. Cold-chain monitoring is non-negotiable regardless of vial size.
A 2mg tesamorelin vial looks identical to a 1mg vial from the outside. Same cap, same lyophilized powder appearance, same reconstitution requirements. The difference only becomes obvious when you run the math on dosing volume, and by then, researchers have already ordered a three-month supply based on incorrect calculations. We've guided hundreds of research teams through peptide procurement, and vial size confusion remains the single most common sourcing error that delays protocols by weeks.
The stakes aren't just inconvenience. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 26 minutes in its active form, meaning dosing precision matters significantly more than with longer-acting peptides. A miscalculated reconstitution volume can result in under-dosing that fails to stimulate pituitary GH secretion or over-dosing that risks adverse events without additional efficacy. Vial size determines every downstream calculation in your protocol.
What is the standard tesamorelin vial size, and why does it vary?
Tesamorelin vial size typically ranges from 1mg to 2mg of lyophilized peptide per vial, with 2mg being the most common research-grade format. Vial size determines reconstitution volume, injection frequency, and monthly supply requirements. A 2mg vial reconstituted with 2mL bacteriostatic water yields 1mg/mL concentration, allowing precise dosing with standard insulin syringes. Suppliers offer different vial sizes to accommodate varying research protocols, from single-dose pilot studies to multi-week continuous administration models.
Yes, tesamorelin vial size directly impacts dosing accuracy and protocol design. But the real issue isn't the vial itself. The confusion arises because most peptide suppliers label vials by total peptide content (e.g., 2mg per vial) rather than per-dose units, leaving researchers to calculate their own reconstitution ratios and injection volumes. The rest of this piece covers exactly how vial size affects reconstitution protocols, how to calculate monthly supply needs based on vial specifications, and what storage mistakes compromise peptide stability regardless of vial size.
Understanding Tesamorelin Vial Size Specifications
Tesamorelin vial size refers to the total amount of lyophilized peptide contained in a single sealed vial, measured in milligrams. The most common tesamorelin vial size formats in research settings are 1mg and 2mg per vial, though some specialized suppliers offer 5mg vials for extended protocols. Unlike pre-filled injection pens used in clinical pharmaceutical formulations, research-grade tesamorelin arrives as a freeze-dried white powder that requires reconstitution with bacteriostatic water before use.
The lyophilization process removes water from the peptide solution under vacuum, preserving the 44-amino-acid sequence structure of tesamorelin while extending shelf life significantly beyond that of liquid formulations. This is why tesamorelin vial size matters for storage logistics. Unreconstituted lyophilized peptides remain stable at −20°C for 24–36 months, while reconstituted solutions must be refrigerated at 2–8°C and used within 28 days. Vial size directly determines how much bacteriostatic water you add during reconstitution, which in turn affects the final concentration and injection volume per dose.
A 2mg tesamorelin vial reconstituted with 2mL bacteriostatic water yields a 1mg/mL solution. If the research protocol calls for a 1mg dose (the standard amount in human clinical trials investigating visceral adipose tissue reduction), you would draw and inject 1mL per administration. If you reconstitute the same 2mg vial with 1mL bacteriostatic water instead, you create a 2mg/mL solution. Meaning a 1mg dose requires only 0.5mL injection volume. Both approaches deliver identical peptide amounts, but the injection volume changes based on reconstitution ratio.
This flexibility is why tesamorelin vial size specifications are critical to document before beginning any research protocol. At Real Peptides, every peptide is synthesized through small-batch production with verified amino-acid sequencing, and vial sizes are clearly labeled with exact milligram content to eliminate guesswork during reconstitution. Researchers working with 1mg vials need to order twice as many units as those using 2mg vials to achieve the same total peptide supply. A detail that significantly impacts budgeting and cold-chain logistics.
Tesamorelin's mechanism of action involves binding to GHRH receptors on anterior pituitary somatotrophs, triggering endogenous growth hormone secretion through a Gαs-protein-coupled pathway that activates adenylyl cyclase. This receptor-mediated activity means dosing precision is non-negotiable. Under-dosing below threshold receptor occupancy produces no measurable GH elevation, while excessive dosing beyond receptor saturation offers no additional efficacy but increases the risk of joint pain, peripheral edema, and insulin resistance. Vial size affects whether your reconstitution protocol supports the precision required for consistent receptor activation across multiple administrations.
Calculating Reconstitution Volume and Dosing Based on Vial Size
The relationship between tesamorelin vial size and reconstitution volume follows a straightforward formula: desired concentration (mg/mL) = total peptide content (mg) ÷ reconstitution volume (mL). If you have a 2mg tesamorelin vial and want a final concentration of 1mg/mL, you add 2mL bacteriostatic water. If you want 0.5mg/mL, you add 4mL. The math is simple, but the implications for injection volume and multi-dose stability are not.
Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-dose vials over the 28-day refrigerated storage period. Using sterile water without preservative reduces shelf life to 72 hours once the vial is punctured, making it unsuitable for protocols that draw multiple doses from a single vial. This is why larger tesamorelin vial sizes (2mg or 5mg) are typically reconstituted with bacteriostatic water rather than sterile water. A 2mg vial reconstituted with 2mL bacteriostatic water supports up to 20 separate 0.1mL injections (if dosing at 0.1mg per injection) over four weeks without contamination risk.
Injection volume practicality is another consideration. Standard insulin syringes range from 0.3mL to 1mL capacity, with 0.01mL (10-unit) graduation marks for precise measurement. A 1mg dose drawn from a 1mg/mL solution requires 1mL injection volume. The maximum capacity of most insulin syringes. Researchers using subcutaneous administration protocols often prefer smaller injection volumes (0.3–0.5mL) for patient comfort, which requires higher-concentration reconstitution. A 2mg tesamorelin vial reconstituted with 1mL bacteriostatic water (yielding 2mg/mL) allows a 1mg dose to be delivered in just 0.5mL injection volume.
Vial size also determines how many administrations you can draw from a single reconstituted vial. A 2mg vial dosed at 1mg per injection provides exactly two doses. A 2mg vial dosed at 0.5mg per injection provides four doses. A 5mg vial dosed at 1mg per injection provides five doses. This calculation becomes critical when designing protocols that span weeks or months. Underestimating vial quantity leaves researchers mid-protocol without supply, while over-ordering increases waste if reconstituted vials expire before all doses are used.
We've worked with research teams that miscalculated their tesamorelin vial size needs by a factor of three because they confused per-vial content with per-dose content. One group ordered 10 vials of 1mg tesamorelin assuming each vial contained ten 1mg doses (a total of 100mg), when in reality they had ordered 10mg total. Enough for ten single doses, not one hundred. Vial labeling clarity matters, and at Real Peptides, every vial is labeled with total milligram content per unit to prevent this exact error. If your protocol requires 60mg of tesamorelin over a 60-day period at 1mg per day, you need thirty 2mg vials or sixty 1mg vials. Not ten.
Storage Requirements and Stability by Vial Size
Tesamorelin vial size doesn't change the peptide's chemical stability requirements, but it does affect how you manage cold-chain logistics and post-reconstitution storage timelines. Unreconstituted lyophilized tesamorelin must be stored at −20°C or colder, where it remains stable for 24–36 months depending on manufacturing date. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. This 28-day window applies regardless of whether you reconstituted a 1mg or 5mg vial.
The freeze-thaw cycle is the most common cause of peptide degradation outside of temperature excursions. Lyophilized peptides tolerate a single freeze-thaw cycle with minimal potency loss, but repeated freezing and thawing disrupts the tertiary structure of the 44-amino-acid chain that defines tesamorelin's receptor-binding activity. This is why researchers working with multi-dose protocols prefer larger tesamorelin vial sizes. Reconstituting a 5mg vial once and storing it refrigerated for four weeks avoids the repeated freeze-thaw exposure that occurs when reconstituting five separate 1mg vials over the same period.
Light exposure also accelerates degradation. Tesamorelin contains methionine and tryptophan residues that oxidize when exposed to UV light, reducing receptor affinity and GH secretagogue potency. Amber glass vials or foil-wrapped clear vials protect against photodegradation during storage. Once reconstituted, the vial should remain refrigerated in its original packaging or a light-blocking container. Leaving reconstituted peptide solutions on a lab bench under fluorescent lighting for even 4–6 hours measurably reduces potency.
Temperature excursions above 8°C cause irreversible denaturation that neither appearance nor home testing can detect. A reconstituted 2mg tesamorelin vial left at room temperature (20–25°C) for 12 hours loses approximately 15–20% potency, even if it's immediately returned to refrigeration afterward. The peptide doesn't change color, doesn't develop particulates, and doesn't smell different. But its ability to activate GHRH receptors is permanently compromised. This is why cold-chain shipping with temperature-monitoring data loggers is non-negotiable for peptide procurement, and why larger vial sizes that minimize the number of shipments reduce cumulative temperature exposure risk.
At Real Peptides, all peptides are shipped in insulated containers with gel ice packs rated for 48-hour cold maintenance, and every shipment includes a temperature indicator strip that irreversibly changes color if the package exceeds 8°C during transit. Researchers receiving tesamorelin vial size orders can verify cold-chain integrity before opening the package. If the indicator shows temperature excursion, the product is replaced at no cost. This level of traceability is what separates research-grade peptide suppliers from generic compounding pharmacies that ship in standard envelopes with no temperature monitoring.
Tesamorelin Vial Size: Dosing Format Comparison
Tesamorelin vial size affects more than just reconstitution math. It determines protocol flexibility, waste management, and cost per dose. Below is a comparison of the three most common vial formats used in research settings.
| Vial Size | Typical Reconstitution Volume | Resulting Concentration | Doses Per Vial (1mg/dose) | Refrigerated Shelf Life Post-Reconstitution | Best Use Case | Professional Assessment |
|---|---|---|---|---|---|---|
| 1mg per vial | 1mL bacteriostatic water | 1mg/mL | 1 dose | 28 days | Single-dose pilot studies, dosing trials where concentration must remain constant across subjects | Minimal waste but requires frequent reconstitution. Suitable for short protocols only |
| 2mg per vial | 2mL bacteriostatic water | 1mg/mL | 2 doses | 28 days | Standard multi-dose protocols, weekly dosing regimens, studies comparing 0.5mg vs 1mg doses | Most common format. Balances multi-dose convenience with manageable injection volumes |
| 5mg per vial | 2.5mL bacteriostatic water | 2mg/mL | 5 doses (at 1mg each) | 28 days | Extended protocols, studies requiring consistent batch sourcing, high-volume labs | Reduces per-dose cost and reconstitution frequency. Requires precise syringe measurement |
The 2mg tesamorelin vial size offers the best balance between dosing flexibility and waste minimization for most research applications. A single reconstitution event supports two to four administrations (depending on dose), fits within the 28-day refrigerated stability window, and allows straightforward 1mg/mL concentration that simplifies syringe measurement. Researchers working with 1mg vials face more frequent reconstitution steps, while those using 5mg vials must ensure their protocol will consume all five doses within four weeks or accept higher waste rates.
What If: Tesamorelin Vial Size Scenarios
What If I Accidentally Reconstitute a 2mg Vial Thinking It Was 1mg?
Label the vial immediately with actual concentration (2mg/original volume) and recalculate injection volume before any administration. If you added 1mL bacteriostatic water expecting a 1mg vial but actually reconstituted 2mg, your solution is 2mg/mL. Double your intended concentration. Drawing 1mL for what you thought was a 1mg dose would deliver 2mg instead, doubling the administered amount and potentially causing joint discomfort, edema, or transient hyperglycemia. Recalculate: for a 1mg dose from a 2mg/mL solution, draw only 0.5mL.
What If My Protocol Requires 1.5mg Doses but My Tesamorelin Vial Size Is 2mg?
Reconstitute the 2mg vial with 2mL bacteriostatic water to create a 1mg/mL solution, then draw 1.5mL per dose. Standard 1mL insulin syringes won't accommodate 1.5mL volume. Use a 3mL syringe with 0.1mL graduation marks instead. Alternatively, reconstitute with 1.33mL bacteriostatic water to yield 1.5mg/mL concentration, allowing a 1.5mg dose to be delivered in exactly 1mL injection volume. Though this non-standard dilution ratio increases measurement error risk during reconstitution.
What If I Need to Travel with Reconstituted Tesamorelin for a Week?
Use a medical-grade insulin cooler rated for 2–8°C maintenance without external power. FRIO wallets use evaporative cooling and maintain refrigeration temperature for 48 hours once activated, but require re-soaking every two days. For trips longer than 72 hours, portable electric coolers with USB charging or battery packs are more reliable. Unreconstituted lyophilized vials tolerate short-term ambient temperature (up to 25°C) for 24–48 hours, making it safer to travel with unreconstituted tesamorelin vial size units and reconstitute on-site if refrigeration access is uncertain.
What If My Reconstituted Vial Looks Cloudy After One Week in the Fridge?
Discard immediately. Cloudiness indicates bacterial contamination or peptide aggregation, both of which compromise safety and efficacy. Properly reconstituted tesamorelin with bacteriostatic water should remain clear and colorless throughout the 28-day refrigerated storage period. Cloudiness most commonly results from non-sterile reconstitution technique (unsterilized vial top, contaminated syringe needle, or using sterile water instead of bacteriostatic water), repeated punctures with the same needle, or temperature excursion that caused protein precipitation.
The Practical Truth About Tesamorelin Vial Size
Here's the honest answer: tesamorelin vial size matters far more than most researchers anticipate when they first design a peptide protocol. The difference between a 1mg and 2mg vial isn't just a factor-of-two supply calculation. It affects reconstitution frequency, injection volume practicality, cold-chain shipping logistics, and whether your 28-day post-reconstitution stability window aligns with your actual dosing schedule. We've seen protocols fail not because the peptide was ineffective, but because vial size planning didn't account for real-world administration constraints.
The vial size you choose should be dictated by three factors: total protocol duration, dosing frequency, and refrigerated storage access. A 12-week study dosing 1mg daily requires 84mg total peptide. That's forty-two 2mg vials or eighty-four 1mg vials. Reconstituting a fresh vial every two days (with 2mg vials) is manageable; reconstituting daily (with 1mg vials) becomes a protocol adherence burden that increases contamination risk with every additional reconstitution event. Conversely, a pilot study testing five different doses across ten subjects benefits from 1mg vials that allow individualized reconstitution ratios without wasting unused peptide.
Cost per milligram typically decreases with larger vial sizes, but only if you can consume the entire vial within the 28-day post-reconstitution window. A 5mg vial that costs 30% less per milligram than five separate 1mg vials offers no savings if you discard 2mg unused because your protocol only required three doses. The math is straightforward: divide total protocol peptide requirement by 28-day consumption capacity to determine optimal vial size. If your dosing schedule consumes 2mg every 10 days, a 2mg vial fits perfectly within stability limits; a 5mg vial would require discarding unused peptide after four weeks.
The biggest mistake researchers make isn't choosing the wrong tesamorelin vial size. It's failing to document vial specifications before scaling from pilot to full study. Switching from 1mg to 2mg vials mid-protocol changes reconstitution procedures, injection volumes, and per-dose cost calculations, introducing variables that confound data interpretation if subjects receive peptide from different vial formats without standardized concentration control. Document your vial size selection in your materials and methods section, and maintain that specification throughout the study duration even if a different size becomes available or less expensive.
If you're procuring tesamorelin for multi-phase research, consider whether your cold storage capacity supports bulk ordering of larger vial sizes versus smaller, more frequent shipments of smaller vials. A −20°C freezer with 50L capacity can store hundreds of 2mg lyophilized vials for 24+ months, allowing you to lock in a single manufacturing batch with verified sequencing and purity. Eliminating batch-to-batch variability as a confounding variable. Smaller labs without dedicated peptide freezers may find that ordering four 2mg vials monthly (8mg total) better matches their refrigerated storage limits than ordering sixteen 2mg vials quarterly, even if the per-vial cost is slightly higher with smaller orders.
The choice becomes obvious when you map vial size against your specific protocol constraints. Calculate total peptide needed, divide by doses per vial, multiply by reconstitution frequency, and factor in your cold-chain logistics. The right tesamorelin vial size is the one that delivers your required total peptide amount with the fewest reconstitution events, fits within your injection volume preferences, and aligns with your refrigerated stability window. Not necessarily the largest or cheapest option per milligram.
If vial size planning feels like an administrative detail that doesn't warrant this level of scrutiny, consider that a single temperature-compromised shipment of sixty 1mg vials represents 60mg of unusable peptide and a 4–6 week re-order delay that halts your entire study. Vial size determines how many individual units are at risk in any single cold-chain failure. Thirty 2mg vials represent the same total peptide as sixty 1mg vials, but half the number of temperature-monitoring points to verify. At Real Peptides, every vial ships with individual temperature verification and verified amino-acid sequencing documentation. But even perfect supplier quality control cannot compensate for vial size choices that don't match your protocol's operational realities.
References
Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
- Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
- Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA